Effects of prednisolone on skeletal muscle contractility in mdx mice

Muscle and Nerve

Volumn 40, Issue 3, 2009, Pages 443-454

  Baltgalvis, Kristen A ^a   Call, Jarrod A ^a   Nikas, Jason B ^a   Lowe, Dawn A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Duchenne muscular dystrophy; Glucocorticoids; Skeletal muscle function

Indexed keywords

PLACEBO; PREDNISOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DUCHENNE MUSCULAR DYSTROPHY; ECCENTRIC MUSCLE CONTRACTION; EXPERIMENTAL MOUSE; EXTENSOR DIGITORUM LONGUS MUSCLE; HISTOLOGY; LOW DRUG DOSE; MALE; MOUSE; MUSCLE CELL; MUSCLE CONTRACTILITY; MUSCLE FORCE; MUSCLE INJURY; MUSCLE STRENGTH; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BODY MASS INDEX; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; MALE; MICE; MICE, INBRED MDX; MUSCLE CONTRACTION; MUSCLE FIBERS, SKELETAL; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; ORGAN SIZE; PREDNISOLONE; TIME FACTORS;

EID: 69749102716     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21327     Document Type: Article

References (49)

1. Anderson JE, McIntosh LM, Poettcker R. Deflazacort but not prednisone improves both muscle repair and fiber growth in diaphragm and limb muscle in vivo in the mdx dystrophic mouse. Muscle Nerve 1996;19:1576-1585. (Pubitemid 26412114)
2. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998;94:557-572. (Pubitemid 28269054)
3. Beenakker EA, Fock JM, Van Tol MJ, Maurits NM, Koopman HM, Brouwer OF, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol 2005;62:128-132. (Pubitemid 40105045)
4. Boer JM, de Meijer EJ, Mank EM, van Ommen GB, den Dunnen JT. Expression profiling in stably regenerating skeletal muscle of dystrophin-deficient mdx mice. Neuromuscul Disord 2002;12(Suppl 1):S118-124.
5. Brooks SV, Faulkner JA. Contractile properties of skeletal muscles from young, adult and aged mice. J Physiol 1988;404:71-82.
6. Burrow KL, Coovert DD, Klein CJ, Bulman DE, Kissel JT, Rammohan KW, et al. Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group. Neurology 1991;41:661-666.
7. Coulton GR, Curtin NA, Morgan JE, Partridge TA. The mdx mouse skeletal muscle myopathy: II. Contractile properties. Neuropathol Appl Neurobiol 1988;14:299-314.
8. Courdier-Fruh I, Barman L, Briguet A, Meier T. Glucocorticoid-mediated regulation of utrophin levels in human muscle fibers. Neuromuscul Disord 2002;12(Suppl 1):S95-104. (Pubitemid 36158779)
9. Croxtall JD, van Hal PT, Choudhury Q, Gilroy DW, Flower RJ. Different glucocorticoids vary in their genomic and nongenomic mechanism of action in A549 cells. Br J Pharmacol 2002;135:511-519. (Pubitemid 34151184)
10. De Luca A, Pierno S, Liantonio A, Cetrone M, Camerino C, Fraysse B, et al. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther 2003;304:453-463. (Pubitemid 36008959)
11. Emery AE. Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord 1991;1:19-29.
12. Fisher I, Abraham D, Bouri K, Hoffman EP, Muntoni F, Morgan J. Prednisolone-induced changes in dystrophic skeletal muscle. FASEB J 2005;19:834-836. (Pubitemid 40617400)
13. Golumbek PT, Keeling RM, Connolly AM. Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout. Neuromuscul Disord 2007;17:376-384.
14. Gordon T, Stein RB. Comparison of force and stiffness in normal and dystrophic mouse muscles. Muscle Nerve 1988;11:819-827. (Pubitemid 18192558)
15. Granchelli JA, Avosso DL, Hudecki MS, Pollina C. Cromolyn increases strength in exercised mdx mice. Res Commun Mol Pathol Pharmacol 1996;91:287-296. (Pubitemid 26150142)
16. Granchelli JA, Pollina C, Hudecki MS. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord 2000;10:235-239. (Pubitemid 30320912)
17. Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993;43:520-527.
18. Hudecki MS, Pollina CM, Granchelli JA, Daly MK, Byrnes T, Wang JC, et al. Strength and endurance in the therapeutic evaluation of prednisolone-treated MDX mice. Res Commun Chem Pathol Pharmacol 1993;79:45-60. (Pubitemid 23039209)
19. Hussein MR, Hamed SA, Mostafa MG, Abu-Dief EE, Kamel NF, Kandil MR. The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies. Int J Exp Pathol 2006;87:451-461.
20. Ingalls CP, Warren GL, Lowe DA, Boorstein DB, Armstrong RB. Differential effects of anesthetics on in vivo skeletal muscle contractile function in the mouse. J Appl Physiol 1996;80:332-340. (Pubitemid 26037127)
21. Jacobs SC, Bootsma AL, Willems PW, Bar PR, Wokke JH. Prednisone can protect against exercise-induced muscle damage. J Neurol 1996;243:410-416.
22. Keeling RM, Golumbek PT, Streif EM, Connolly AM. Weekly oral prednisolone improves survival and strength in male mdx mice. Muscle Nerve 2007;35:43-48.
23. Landisch RM, Kosir AM, Nelson SA, Baltgalvis KA, Lowe DA. Adaptive and nonadaptive responses to voluntary wheel running by mdx mice. Muscle Nerve 2008;38:1290-1293.
24. Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, Habelitz S, et al. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 2006;21:466-476. (Pubitemid 43306568)
25. Louboutin JP, Fichter-Gagnepain V, Pastoret C, Thaon E, Noireaud J, Sebille A, et al. Morphological and functional study of extensor digitorum longus muscle regeneration after iterative crush lesions in mdx mouse. Neuromuscul Disord 1995;5:489-500.
26. Lowe DA, Warren GL, Hayes DA, Farmer MA, Armstrong RB. Eccentric contraction-induced injury of mouse soleus muscle: effect of varying [Ca2+]o. J Appl Physiol 1994;76:1445-1453. (Pubitemid 24125656)
27. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008:CD003725.
28. Matecki S, Guibinga GH, Petrof BJ. Regenerative capacity of the dystrophic (mdx) diaphragm after induced injury. Am J Physiol Regul Integr Comp Physiol 2004;287:R961-968. (Pubitemid 39280485)
29. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989;320:1592-1597.
30. Metzinger L, Passaquin AC, Warter JM, Poindron P. alpha- Methylprednisolone promotes skeletal myogenesis in dystrophin-deficient and control mouse cultures. Neurosci Lett 1993;155:171-174. (Pubitemid 23190291)
31. Moran AL, Nelson SA, Landisch RM, Warren GL, Lowe DA. Estradiol replacement reverses ovariectomy-induced muscle contractile and myosin dysfunction in mature female mice. J Appl Physiol 2007;102:1387-1393.
32. Moran AL, Warren GL, Lowe DA. Soleus and EDL muscle contractility across the lifespan of female C57BL/6 mice. Exp Gerontol 2005;40:966-975.
33. Pasquini F, Guerin C, Blake D, Davies K, Karpati G, Holland P. The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells. Neuromuscul Disord 1995;5:105-114.
34. Passaquin AC, Metzinger L, Leger JJ, Warter JM, Poindron P. Prednisolone enhances myogenesis and dystrophin-related protein in skeletal muscle cell cultures from mdx mouse. J Neurosci Res 1993;35:363-372. (Pubitemid 23195640)
35. Pastoret C, Sebille A. Age-related differences in regeneration of dystrophic (mdx) and normal muscle in the mouse. Muscle Nerve 1995;18:1147-1154.
36. Payne ET, Yasuda N, Bourgeois JM, Devries MC, Rodriguez MC, Yousuf J, et al. Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve 2006;33:66-77. (Pubitemid 43062988)
37. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 1993;90:3710-3714. (Pubitemid 23111437)
38. Rahman MM, Hannan MA, Mondol BA, Bhoumick NB, Haque A. Prednisolone in Duchenne muscular dystrophy. Bangladesh Med Res Counc Bull 2001;27:38-42.
39. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989;244:1578-1580. (Pubitemid 19189735)
40. Sklar RM, Brown RH Jr. Methylprednisolone increases dystrophin levels by inhibiting myotube death during myogenesis of normal human muscle in vitro. J Neurol Sci 1991;101:73-81.
41. Stein RB, Gordon T. Nonlinear stiffness - force relationships in whole mammalian skeletal muscles. Can J Physiol Pharmacol 1986;64:1236-1244. (Pubitemid 17201501)
42. Turk R, Sterrenburg E, de Meijer EJ, van Ommen GJ, den Dunnen JT, t Hoen PA. Muscle regeneration in dystrophin-deficient mdx mice studied by gene expression profiling. BMC Genomics 2005;6:98.
43. Warren GL, Hayes DA, Lowe DA, Prior BM, Armstrong RB. Materials fatigue initiates eccentric contraction-induced injury in rat soleus muscle. J Physiol 1993;464:477-489. (Pubitemid 23169327)
44. Warren GL, Hayes DA, Lowe DA, Williams JH, Armstrong RB. Eccentric contraction-induced injury in normal and hindlimb-suspended mouse soleus and EDL muscles. J Appl Physiol 1994;77:1421-1430. (Pubitemid 24299399)
45. Wehling-Henricks M, Lee JJ, Tidball JG. Prednisolone decreases cellular adhesion molecules required for inflammatory cell infiltration in dystrophin-deficient skeletal muscle. Neuromuscul Disord 2004;14:483-490. (Pubitemid 39141703)
46. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274-282.
47. Weller B, Karpati G, Carpenter S. Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions. J Neurol Sci 1990;100:9-13.
48. Weller B, Massa R, Karpati G, Carpenter S. Glucocorticoids and immunosuppressants do not change the prevalence of necrosis and regeneration in mdx skeletal muscles. Muscle Nerve 1991;14:771-774.
49. Yang L, Luo J, Petrof BJ. Corticosteroid therapy does not alter the threshold for contraction-induced injury in dystrophic (mdx) mouse diaphragm. Muscle Nerve 1998;21:394-397. (Pubitemid 28096050)